Treatment Advances Fail to Improve Mesothelioma Survival Trends
A new report shows mesothelioma survival trends have remained steady for decades, despite new drugs, new surgery techniques, and the…
-
-
Mesothelioma-Related Weight Loss: Synthetic Cannabinoid Might Help
The first patient has been treated in the trial of a new drug that might help people suffering from mesothelioma-related… -
Triple-Modality Therapy May Improve Mesothelioma Outcomes, Study Suggests
A Canadian study suggests that triple-modality therapy with radiotherapy, immunotherapy, and surgery may extend the lives of people with malignant… -
Europe | Genetics | Immunotherapy | International | Research | Treatments
Long-Term Mesothelioma Survival With Immunotherapy Combination
An immunotherapy combination of tremelimumab and durvalumab has resulted in long-term survival for some mesothelioma patients in a new follow-up… -
Canadian Study Highlights Occupational Mesothelioma Risk
A new study of more than 2 million Canadian workers is shining a spotlight on the occupational mesothelioma risk from… -
Europe | International | New Studies | Research | Surgery | Treatments
CRS/HIPEC Procedure Has Improved Over Time, Study Finds
A new French study contains some good news for people considering the CRS/HIPEC procedure for peritoneal mesothelioma. The CRS/HIPEC procedure… -
Diagnosis | Europe | International | Prognosis | Scans
Prognostic Value of PET/CT in Pleural Mesothelioma Patients
New data highlights the prognostic value of PET/CT scans for patients with malignant pleural mesothelioma. Pleural mesothelioma is a rare… -
Mesothelioma Clinical Trials: Eligibility May Be Too Strict, Study Finds
A new Australian study suggests that too many people are being left out of mesothelioma clinical trials under current trial… -
Which Mesothelioma Patients will Benefit from Second-Line Chemotherapy
Japanese oncologists say they have found a way to help predict which peritoneal mesothelioma patients are most likely to get… -
Phase 3 Clinical Trial to Test Durvalumab for Mesothelioma
A potential new first-line immunotherapy treatment for mesothelioma is now recruiting patients for a phase 3 clinical trial. The trial…
